Compare Essex Property Trust, Inc. (ESS) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Essex Property Trust, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Essex Property Trust, Inc. trades at $269.13 (market cap $17.23B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 4.4× Essex Property Trust, Inc.'s market cap, and Essex Property Trust, Inc. pays the higher dividend (3.86%). Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| ESS | REGN | |
|---|---|---|
Market Cap | $17.23B | $76.40B |
Volume | 346,109 | 626,381 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $852.03 |
52-Week Low | $239.61 | $557.73 |
Typical Hold Time | 111 Days | 107 Days |
Enterprise Value | $23.82B | $71.12B |
Dividend Yield | 3.86% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ESS trades at $268.05, down 1.63% with bearish technical signals. The company reported mixed Q2 2026 results, beating FFO estimates but missing EPS expectations. Strong operational performance and litigation resolution provide fundamental support, though high valuation ratios and debt levels present concerns. Recent institutional buying and a $2.59 dividend declaration highlight investor confidence.
Outlook remains cautiously optimistic with a $303.41 consensus price target offering 13% upside. Key risks include earnings volatility, high leverage, and regional economic exposure. The stock presents a balanced opportunity for income-focused investors seeking quality REIT exposure with disciplined risk management.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Essex Property Trust, Inc.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
